Stock 688298 ZHEJIANG ORIENT GENE BIOTECH CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhejiang Orient Gene Biotech Co.,Ltd

Equities

688298

CNE100003RM8

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
29.56 CNY +0.14% Intraday chart for Zhejiang Orient Gene Biotech Co.,Ltd +6.48% -17.34%
Apr. 29 Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 23 Zhejiang Orient Gene Biotech's Unit Gets US FDA's Nod to Register Two Products MT

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 24,360 27,660 12,955 7,209
Enterprise Value (EV) 1 22,122 21,381 5,279 2,601
P/E ratio 14.2 x 5.62 x 6.26 x -18.2 x
Yield 2.07% 2.68% 2.59% -
Capitalization / Revenue 7.46 x 2.72 x 1.48 x 8.79 x
EV / Revenue 6.77 x 2.1 x 0.6 x 3.17 x
EV / EBITDA 11 x 3.66 x 2.26 x -9.39 x
EV / FCF 17.4 x 6.36 x 3.49 x -1.17 x
FCF Yield 5.76% 15.7% 28.7% -85.5%
Price to Book 9.96 x 4.03 x 1.59 x 0.97 x
Nbr of stocks (in thousands) 201,601 201,601 201,601 201,600
Reference price 2 120.8 137.2 64.26 35.76
Announcement Date 4/28/21 4/27/22 4/27/23 4/29/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 285.9 367.4 3,265 10,169 8,768 820.2
EBITDA 1 74.72 90.2 2,019 5,849 2,338 -276.9
EBIT 1 69.24 83.82 2,012 5,820 2,260 -428.2
Operating Margin 24.22% 22.82% 61.61% 57.23% 25.78% -52.21%
Earnings before Tax (EBT) 1 77 91.3 1,974 5,770 2,471 -404.2
Net income 1 63.96 82.11 1,677 4,920 2,068 -397.6
Net margin 22.37% 22.35% 51.37% 48.38% 23.58% -48.48%
EPS 2 0.4345 0.5417 8.500 24.40 10.26 -1.970
Free Cash Flow 1 0.2491 14.59 1,274 3,361 1,513 -2,223
FCF margin 0.09% 3.97% 39.01% 33.05% 17.25% -271.06%
FCF Conversion (EBITDA) 0.33% 16.18% 63.1% 57.47% 64.72% -
FCF Conversion (Net income) 0.39% 17.77% 75.95% 68.31% 73.16% -
Dividend per Share 2 0.2083 0.1250 2.500 3.679 1.667 -
Announcement Date 1/6/20 4/27/20 4/28/21 4/27/22 4/27/23 4/29/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 52.6 58.4 2,238 6,279 7,675 4,609
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 0.25 14.6 1,274 3,361 1,513 -2,223
ROE (net income / shareholders' equity) 37% 33.5% 124% 106% 27.6% -5.27%
ROA (Net income/ Total Assets) 14.5% 15% 63.9% 58% 14.4% -2.72%
Assets 1 441.1 547.9 2,625 8,488 14,404 14,633
Book Value Per Share 2 1.330 1.660 12.10 34.00 40.50 36.90
Cash Flow per Share 2 0.6800 0.5700 10.10 30.20 32.70 20.70
Capex 1 18.9 11.9 127 508 1,052 996
Capex / Sales 6.6% 3.24% 3.89% 4.99% 12% 121.45%
Announcement Date 1/6/20 4/27/20 4/28/21 4/27/22 4/27/23 4/29/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
ZHEJIANG ORIENT GENE BIOTECH CO.,LTD Stock Zhejiang Orient Gene Biotech Co.,Ltd
-17.34% 823M
BIOMÉRIEUX Stock bioMérieux
-1.89% 12.56B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-9.59% 7.68B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
-1.31% 5.29B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+21.82% 5.24B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
+0.02% 4.57B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.89% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+6.42% 2.6B
VITROLIFE AB Stock Vitrolife AB
-10.02% 2.2B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-8.29% 1.79B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 688298 Stock
  4. Financials Zhejiang Orient Gene Biotech Co.,Ltd